This is a rare type of leukemia that affects the blood and bone marrow. It's characterized by abnormal white blood cells that look like they have hair.
Every report comes from a Lived member, sent anonymously.
Have you tried Cladribine for Hairy Cell Leukemia?
Hairy cell leukemia is a rare, slow-growing cancer of the blood and bone marrow. It starts in B lymphocytes, white blood cells that normally make antibodies to fight infection. Under a microscope the abnormal cells have fine, hair-like projections around their edges, which gives the disease its name. The leukemia cells collect in the bone marrow, where blood is made, and in the spleen. As they crowd the marrow, it makes fewer healthy red blood cells, infection-fighting white blood cells and platelets. That shortfall explains most of what people notice: tiredness or breathlessness from anemia, frequent or unusual infections, and easy bruising or bleeding. An enlarged spleen can cause a feeling of fullness or discomfort below the ribs on the left side. Some people have no symptoms at all and learn they have the disease from a routine blood test. Hairy cell leukemia is different from chronic lymphocytic leukemia (CLL), the more common slow-growing leukemia of adults, and from a few rare look-alike diseases, including one once called hairy cell leukemia variant. Those behave differently and need different treatment, so getting the exact diagnosis matters.
The cause of hairy cell leukemia is not known. In more than 90% of cases, the leukemia cells carry a change in a gene called BRAF (the V600E mutation) that keeps a growth signal inside the cell switched on. This change arises in the leukemia cells during a person's life. It is not an inherited gene, and cases within the same family are rare. The disease is about five times more common in men than in women and is usually diagnosed in the late 50s or early 60s. Studies have linked it with farming and with exposure to pesticides, petroleum products, diesel fumes and ionizing radiation. These are associations seen across groups of people, not proven causes, and most people with hairy cell leukemia have no such exposure.
Hairy cell leukemia is often first suspected from a complete blood count (CBC), the routine test that counts red cells, white cells and platelets. A typical pattern is low levels of more than one of these, often with very few monocytes, a type of white blood cell. Unlike many leukemias, the total white cell count is usually low rather than high. A specialist then examines a blood sample under the microscope for the characteristic hairy cells. Confirming the diagnosis takes several tests together. Flow cytometry reads the markers on the surface of the abnormal cells, which separates hairy cell leukemia from look-alike diseases. A bone marrow biopsy, in which a needle removes a small sample of marrow and bone from the back of the hip after the area is numbed, shows how much of the marrow the leukemia has taken over. Testing for the BRAF V600E mutation supports the diagnosis and becomes important later if targeted treatment is considered. Kidney and liver tests, hepatitis screening and often a CT scan (a detailed computerized X-ray) to measure the spleen help plan treatment. There is no staging system like the one used for many solid cancers. The key question instead is whether the disease needs treatment now, judged by blood counts, symptoms and the size of the spleen.
Not everyone needs treatment right away. Because the disease can stay stable for long periods, people with acceptable blood counts and no symptoms are usually monitored with regular blood tests, an approach called watch and wait. Treatment generally starts when counts fall low enough to raise the risk of anemia, bleeding or infection, or when symptoms such as fevers, night sweats or weight loss, a troublesome enlarged spleen, or repeated infections appear. Specialists commonly use thresholds such as a hemoglobin (the oxygen-carrying protein in red blood cells) below 11 g/dL, a platelet count below 100,000 per microliter, or a neutrophil count (the main infection-fighting white cell) below 1,000 per microliter. The standard first treatment is a short course of a purine analog, a type of chemotherapy that is particularly effective against hairy cells. Cladribine is the most common choice, usually given as an injection under the skin once a day for five days or as a continuous infusion into a vein. Pentostatin, given into a vein every two weeks for up to a year, is an alternative. Many specialists now add rituximab, an antibody infusion that targets B cells, because the combination clears more of the remaining disease and responses tend to last longer. Most people respond, and remissions often last many years. The main trade-off is that these drugs lower blood counts further for a period before they recover, so the risk of serious infection is highest early on. Doctors usually wait until an active infection is under control before starting, and they may choose a different approach for people with significant kidney disease. If the leukemia comes back after a long remission, the same type of treatment often works again. When it returns quickly or does not respond, options include pills that block the BRAF signal, such as vemurafenib, usually combined with rituximab. These do not suppress the bone marrow, but they have their own side effects, including rashes, sun sensitivity, joint pain and new skin cancers that need regular checks. Other targeted drugs and clinical trials are available for later relapses. Surgery to remove the spleen, the main treatment before these drugs existed, remains an option in selected situations.
For most people, hairy cell leukemia is a long-term condition that can be controlled well. After treatment, blood counts usually recover gradually, and many people stay in remission for years. The disease can return, sometimes after a long interval, and re-treatment often brings another remission. Many people therefore experience it as a chronic illness with long quiet periods rather than a single episode. The months after chemotherapy call for the most care, because the immune system is weakest then. Preventive antibiotic and antiviral medicines are commonly prescribed for at least six months after treatment to guard against a particular kind of pneumonia and against shingles. Vaccines against flu, COVID-19 and pneumococcal pneumonia are ideally given before treatment begins. Follow-up continues long term, with regular blood counts and examinations to catch a return early. People with hairy cell leukemia also have a higher risk of other cancers, partly from the disease and partly from treatment, so a yearly skin examination by a dermatologist is recommended. Autoimmune problems, in which the immune system attacks the body's own tissues, such as joint inflammation or destruction of blood cells, affect a meaningful minority of people and are worth raising with the care team if new symptoms appear.
See a doctor about ongoing tiredness, infections that keep coming back, easy bruising or bleeding, or a feeling of fullness below the ribs, particularly if a blood test has already shown low counts. For people already diagnosed, symptoms like these returning, or counts falling on routine tests, are reasons to arrange a review, because they may mean the leukemia is active again. During treatment and in the months after it, contact your care team right away for a fever of 100.5°F (38°C) or higher, chills, or other signs of infection such as a new cough, sore throat or pain when urinating. Infections at this stage can become serious quickly. Check with the team before taking medicine to bring a fever down, since it can hide the warning sign.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hairy Cell Leukemia is like, what's helped you, or ask the community a question.